Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062710 · ClinicalTrials.gov registry record · Phase 4
Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo
A Phase 4 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT02062710: Completed Phase 4 study, sponsored by Montefiore Medical Center.
NCT02062710 is a Phase 4 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 22 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02062710, a Phase 4 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antitussive (cough-suppressing) effects of two liquid medications: a combination of diphenhydramine and phenylephrine in a naturally cocoa flavoring, and, dextromethorphan syrup, compared with placebo.
Primary Outcome
increase in C5 (decrease in cough reflex sensitivity). Capsaicin cough challenge involves subjects breathing in incremental doubling concentrations of aerosolized capsaicin, 1 minute apart, until the concentration of capsaicin (micromolar) inducing 5 or more coughs (C5) is reached.
Interventions
- DRUG diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo
- DRUG diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan
- DRUG dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo
- DRUG dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa
- DRUG placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
What the finished NCT02062710 record still lists
NCT02062710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo is the first listed.
NCT02062710 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02062710 about?
NCT02062710 is a clinical study titled "Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo". The purpose of this study is to evaluate the antitussive (cough-suppressing) effects of two liquid medications: a combination of diphenhydramine and phenylephrine in a naturally cocoa flavoring, and, dextromethorphan syrup, compared with placebo.
What is the current status of trial NCT02062710?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2014-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02062710?
The interventions under investigation include: diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo (DRUG), diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan (DRUG), dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo (DRUG), dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa (DRUG), placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT02062710?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02062710's enrollment target sits among peer trials
22 1731st of 2000 higher than 259 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia